ASH Hematologic Malignancies

Conference Coverage

CLL: The initial work-up

CHICAGO – Molecular testing has prognostic value, but still doesn’t drive treatment under updated iwCLL guidelines.

Conference Coverage

CML outcomes in the age of TKIs

Major molecular response rates at 12 months were better among CML patients treated with dasatinib/nilotinib vs. imatinib for first-line therapy,...

Pages